Logo 1 Logo 2

Clinical Trial Details

Trial ID: L0631
Source ID: NCT01599507
Associated Drug: Fg-4592
Title: Study of FG-4592 in Subjects With Chronic Kidney Disease in China
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Anemia in Chronic Kidney Disease
Interventions: DRUG: FG-4592|DRUG: Placebo
Outcome Measures: Primary: Maximum change in hemoglobin by Week 9 from baseline, Week 9 | Secondary: Proportion of subjects achieving a target Hb level ≥11 g/dL by Weeks 5,6,7,8 and 9., Week 9|Proportion of subjects with a Hb increase from baseline ≥1.0 g/dL., Week 9
Sponsor/Collaborators: Sponsor: FibroGen
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 91
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2011-12
Completion Date: 2013-01
Results First Posted:
Last Update Posted: 2014-03-03
Locations: Peking Union Medical College Hospital, Beijing, China|Peking University First Hospital, Beijing, China|Sichuan Provincial People's Hospital, Chengdu, China|West China Hospital, Chengdu, China|First affiliated hospital of Dalian medical university, DaLian, China|First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China|Zhejiang University No 1. Hospital, Hangzhou, China|Chang Zheng Hospital, Shanghai, China|Huashan Hospital, Shanghai, China|Renji Hospital, Shanghai, China|RuiJin Hospital, Shanghai, China|XinHua Hospital, Shanghai, China|Shenzhen People's Hospital, Shenzhen, China
URL: https://clinicaltrials.gov/show/NCT01599507